Pfizer Income from Discontinued Operations 2010-2024 | PFE
Pfizer annual/quarterly income from discontinued operations history and growth rate from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
- Pfizer income from discontinued operations for the quarter ending September 30, 2024 was $-0.008B, a 166.67% decline year-over-year.
- Pfizer income from discontinued operations for the twelve months ending September 30, 2024 was $-22M, a 269.23% decline year-over-year.
- Pfizer annual income from discontinued operations for 2023 was $-0.015B, a 350% decline from 2022.
- Pfizer annual income from discontinued operations for 2022 was $0.006B, a 101.38% decline from 2021.
- Pfizer annual income from discontinued operations for 2021 was $-0.434B, a 117.16% decline from 2020.
Pfizer Annual Income from Discontinued Operations
(Millions of US $) |
| 2023 |
$-15 |
| 2022 |
$6 |
| 2021 |
$-434 |
| 2020 |
$2,529 |
| 2019 |
$5,318 |
| 2018 |
$7,328 |
| 2017 |
$2 |
| 2016 |
$16 |
| 2015 |
$11 |
| 2014 |
$48 |
| 2013 |
$10,662 |
| 2012 |
$5,577 |
| 2011 |
$2,189 |
| 2010 |
$-30 |
| 2009 |
$114 |
Pfizer Quarterly Income from Discontinued Operations
(Millions of US $) |
| 2024-09-30 |
$-8 |
| 2024-06-30 |
$17 |
| 2024-03-31 |
$-5 |
| 2023-12-31 |
$-26 |
| 2023-09-30 |
$12 |
| 2023-06-30 |
$-2 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$2 |
| 2022-09-30 |
$-21 |
| 2022-06-30 |
$34 |
| 2022-03-31 |
$-9 |
| 2021-12-31 |
$-186 |
| 2021-09-30 |
$-13 |
| 2021-06-30 |
$-236 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$195 |
| 2020-09-30 |
$560 |
| 2020-06-30 |
$893 |
| 2020-03-31 |
$881 |
| 2019-12-31 |
$5,314 |
| 2019-09-30 |
$4 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
$7,318 |
| 2018-09-30 |
$11 |
| 2018-06-30 |
|
| 2018-03-31 |
$-1 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$2 |
| 2017-03-31 |
|
| 2016-12-31 |
$15 |
| 2016-09-30 |
|
| 2016-06-30 |
$1 |
| 2016-03-31 |
|
| 2015-12-31 |
$-3 |
| 2015-09-30 |
$8 |
| 2015-06-30 |
$1 |
| 2015-03-31 |
$5 |
| 2014-12-31 |
$-22 |
| 2014-09-30 |
$-3 |
| 2014-06-30 |
|
| 2014-03-31 |
$73 |
| 2013-12-31 |
$-57 |
| 2013-09-30 |
$11 |
| 2013-06-30 |
$10,559 |
| 2013-03-31 |
$149 |
| 2012-12-31 |
$5,013 |
| 2012-09-30 |
$225 |
| 2012-06-30 |
$260 |
| 2012-03-31 |
$79 |
| 2011-12-31 |
$658 |
| 2011-09-30 |
$1,424 |
| 2011-06-30 |
$97 |
| 2011-03-31 |
$10 |
| 2010-12-31 |
$-97 |
| 2010-09-30 |
$15 |
| 2010-06-30 |
$31 |
| 2010-03-31 |
$21 |
| 2009-12-31 |
$108 |
| 2009-09-30 |
$2 |
| 2009-06-30 |
$3 |
| 2009-03-31 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$145.358B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
